biological response modifiers

Summary

Summary: Biological or synthetic agents that are capable of eliciting specific and/or non-specific effects on immune responsiveness, thereby ultimately leading to an improvement in overall health of the patient. These agents can be further subcategorized into those that facilitate a normal immune response, those that stimulate the immune response, those that are capable of inducing noncytotoxic immunosuppression, and those that increase the ability of the host to tolerate damage by the cytotoxic modalities of the treatment.

Top Publications

  1. ncbi Adverse reactions to biological modifiers
    Richard W Weber
    Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado, USA
    Curr Opin Allergy Clin Immunol 4:277-83. 2004
  2. pmc Psoriatic arthritis treatment: biological response modifiers
    P J Mease
    Seattle Rheumatology Associates, 1101 Madison St, 10th Floor, Seattle, WA 98104, USA
    Ann Rheum Dis 64:ii78-82. 2005
  3. ncbi Laboratory monitoring of biologic therapies
    J J Cush
    Rheumatology and Clinical Immunology, Presbyterian Hospital of Dallas, 8200 Walnut Hill Lane, Dallas, TX 75231 4496, USA
    Clin Exp Rheumatol 23:S90-2. 2005
  4. ncbi The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation
    Salvatore Cuzzocrea
    Institute of Pharmacology, School of Medicine, University of Messina, Messina, Italy
    Mol Pharmacol 61:997-1007. 2002
  5. ncbi 15d-PGJ(2) is acting as a 'dual agent' on the regulation of COX-2 expression in human osteoarthritic chondrocytes
    H Fahmi
    Osteoarthritis Research Unit, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Quebec, Canada
    Osteoarthritis Cartilage 10:845-8. 2002
  6. ncbi Platelet storage lesion: an update on the impact of various leukoreduction processes on the biological response modifiers
    Jerard Seghatchian
    Blood Component Technology and Thrombosis Haemostasis Consultancy, 50 Primrose Hill Road, London NW3 3AA, UK
    Transfus Apher Sci 34:125-30. 2006
  7. ncbi Structural development of biological response modifiers based on thalidomide
    Yuichi Hashimoto
    Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1 1 1 Yayoi, Bunkyo ku, Tokyo 113 0032, Japan
    Bioorg Med Chem 10:461-79. 2002
  8. pmc Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis
    William L Macias
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Crit Care 9:R607-22. 2005
  9. ncbi Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1
    Saranette Cheng
    Osteoarthritis Research Unit, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Canada
    J Biol Chem 279:22057-65. 2004
  10. ncbi Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers
    U K Buchwald
    Division of Infectious Diseases, Department of Medicine and Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Curr Pharm Des 9:945-68. 2003

Detail Information

Publications225 found, 100 shown here

  1. ncbi Adverse reactions to biological modifiers
    Richard W Weber
    Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado, USA
    Curr Opin Allergy Clin Immunol 4:277-83. 2004
    ..This review addresses adverse responses to these agents...
  2. pmc Psoriatic arthritis treatment: biological response modifiers
    P J Mease
    Seattle Rheumatology Associates, 1101 Madison St, 10th Floor, Seattle, WA 98104, USA
    Ann Rheum Dis 64:ii78-82. 2005
    ..Also, it will be useful to learn more about the effects of combining traditional disease modifying drugs and the newer biologicals...
  3. ncbi Laboratory monitoring of biologic therapies
    J J Cush
    Rheumatology and Clinical Immunology, Presbyterian Hospital of Dallas, 8200 Walnut Hill Lane, Dallas, TX 75231 4496, USA
    Clin Exp Rheumatol 23:S90-2. 2005
    ..Tuberculin skin testing using PPD is recommended before starting treatment with any TNF inhibitor...
  4. ncbi The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation
    Salvatore Cuzzocrea
    Institute of Pharmacology, School of Medicine, University of Messina, Messina, Italy
    Mol Pharmacol 61:997-1007. 2002
    ..Thus, 15d-PGJ(2) reduces the development of acute and chronic inflammation. Therefore, the cyclopentenone prostaglandin 15d-PGJ(2) may be useful in the therapy of acute and chronic inflammation...
  5. ncbi 15d-PGJ(2) is acting as a 'dual agent' on the regulation of COX-2 expression in human osteoarthritic chondrocytes
    H Fahmi
    Osteoarthritis Research Unit, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Quebec, Canada
    Osteoarthritis Cartilage 10:845-8. 2002
    ..This study showed that the PPARgamma agonist, 15d-PGJ(2), exerts a dual effect on COX-2 production. The mechanisms by which 15d-PGJ(2) favors COX-2 production will be discussed...
  6. ncbi Platelet storage lesion: an update on the impact of various leukoreduction processes on the biological response modifiers
    Jerard Seghatchian
    Blood Component Technology and Thrombosis Haemostasis Consultancy, 50 Primrose Hill Road, London NW3 3AA, UK
    Transfus Apher Sci 34:125-30. 2006
    ..between and within groups, in terms of various laboratory markers of biocompatibility and major biological response modifiers, indicating that much still remains to be done on various aspects of quality improvement to fully ..
  7. ncbi Structural development of biological response modifiers based on thalidomide
    Yuichi Hashimoto
    Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1 1 1 Yayoi, Bunkyo ku, Tokyo 113 0032, Japan
    Bioorg Med Chem 10:461-79. 2002
    ....
  8. pmc Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis
    William L Macias
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Crit Care 9:R607-22. 2005
    ..Such an interaction might warrant a change in the assumptions that underlie current trial designs...
  9. ncbi Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1
    Saranette Cheng
    Osteoarthritis Research Unit, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Canada
    J Biol Chem 279:22057-65. 2004
    ..These data define mPGES-1 and Egr-1 as novel targets of PPARgamma and suggest that inhibition of mPGES-1 gene transcription may be one of the mechanisms by which PPARgamma regulates inflammatory responses...
  10. ncbi Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers
    U K Buchwald
    Division of Infectious Diseases, Department of Medicine and Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Curr Pharm Des 9:945-68. 2003
    ..In this paper, we review the historical underpinnings and present and future applications of immune therapy for infectious diseases in light of current challenges to the field...
  11. ncbi Biological response modifiers in the management of rheumatoid arthritis
    Stan G Louie
    School of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA 90033, USA
    Am J Health Syst Pharm 60:346-55. 2003
    The management of rheumatoid arthritis (RA) with biological response modifiers (BRMs) is reviewed...
  12. ncbi Polysaccharide biological response modifiers
    M Y K Leung
    Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, N T, Hong Kong, People s Republic of China
    Immunol Lett 105:101-14. 2006
    b>Biological response modifiers (BRMs) are substances which augment immune response...
  13. ncbi Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers
    Alexander V Kabanov
    College of Pharmacy, Department of Pharmaceutical Sciences, Nebraska Medical Center, Omaha 68198 6025, USA
    Crit Rev Ther Drug Carrier Syst 19:1-72. 2002
    ..Finally, Pluronic formulations were shown to enhance transgene expression in the body. This opens new possibilities for the use of Pluronic in gene therapies...
  14. ncbi Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists
    H H Lee
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, D 10117 Berlin, Germany
    Br J Dermatol 156:486-91. 2007
    ..Patients with rheumatic diseases receiving antitumour necrosis factor (TNF)-alpha-based treatment may develop cutaneous reactions...
  15. pmc Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study
    S Guignard
    Rene Descartes University, Medicine Faculty, APHP, Cochin Hospital, Rheumatology B Department, Paris, France
    Ann Rheum Dis 65:1631-4. 2006
    ..To evaluate the efficacy of anti-tumour necrosis factor (TNF) treatments (given for rheumatological manifestations) in reducing uveitis flares in patients with spondylarthropathy in daily practice...
  16. ncbi Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer?
    Bart G Denys
    Department of Internal Medicine, AZ Sint Jan AV, Ruddershove 10, B 8000 Brugge, Belgium
    Clin Sci (Lond) 112:281-9. 2007
    ..Pending publication of the RCTs, the use of TNF-alpha blockade in sarcoidosis should remain in the realm of experimental treatment...
  17. ncbi Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
    Roy Fleischmann
    The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235, USA
    Drugs Aging 24:239-54. 2007
    ..Only by understanding the risks and benefits of therapy in the older age group can a true risk : benefit profile for etanercept, and ultimately other anti-TNFalpha therapies, be determined by the practising physician and the patient...
  18. pmc Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis
    M C Hochberg
    Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201 USA
    Ann Rheum Dis 62:ii13-6. 2003
    ....
  19. ncbi Psoriatic arthritis: a guide for dermatology nurses
    Alice B Gottlieb
    University of Medicine and Dentistry of New Jersey UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    Dermatol Nurs 15:107-10, 113-8; quiz 119. 2003
    ..It is imperative that dermatology nurses learn more about the basic immunology of psoriasis and PsA and the role of immunomodulation in their treatments...
  20. ncbi Therapeutic implications for interferon-alpha in arthritis: a pilot study
    Thomas Wong
    Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada
    J Rheumatol 30:934-40. 2003
    ..To evaluate the therapeutic potential of interferon-a (IFN-a) in osteoarthritis (OA) and rheumatoid arthritis (RA) by examining regulation of cytokine antagonist expression...
  21. ncbi The use of biological agents in the treatment of rheumatoid arthritis
    Peng Thim Fan
    Ann Acad Med Singapore 36:128-34. 2007
    ..In this review, the efficacy and side effects of these agents, their impact on current clinical practice and future trends are discussed...
  22. ncbi TNF involvement and anti-TNF therapy of reactive and unclassified arthritis
    R Meador
    Hospital of University of Pennsylvania, Philadelphia VA Medical Center, 19104, USA
    Clin Exp Rheumatol 20:S130-4. 2002
    ..The clinical effect on a potential underlying infection is not known, but several studies have suggested at least short-term effectiveness and safety of anti-TNF-alpha therapy in reactive and unclassified arthritis...
  23. ncbi TNF-alpha antagonists for the treatment of juvenile-onset spondyloarthritides
    G Homeff
    Department of Paediatrics, Martin Luther University Halle Wittenberg, Halle, Germany
    Clin Exp Rheumatol 20:S137-42. 2002
    ..However, without further studies no recommendations can be provided for indication for treatment, dosing, intervals and duration of treatment...
  24. ncbi Anti-TNF therapy for other inflammatory conditions
    Z Tutuncu
    The Center for Innovative Therapy, Division of Rheumatology Allergy and Immunology, UCSD, School of Medicine, La Jolla, California, USA
    Clin Exp Rheumatol 20:S146-51. 2002
    ..However, whether anti-TNFalpha therapy can be safely and efficaciously applied to these other inflammatory disorders requires further controlled studies...
  25. ncbi Side effects of anti-TNF therapy: current knowledge
    C Antoni
    Department of Medicine III, University Erlangen Nuernberg, Erlangen, Germany
    Clin Exp Rheumatol 20:S152-7. 2002
    ..Sufficient knowledge about these partly specific side effects is critical for rheumatologists who treat their patients with these very effective biologic drugs...
  26. ncbi Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA
    Cutis 71:25-9. 2003
    ..The structure and mechanism of each drug will be reviewed, as well as the most recent clinical experience and safety data. The first article of this review will focus on the therapies that inhibit tumor necrosis factor alpha (TNF-alpha)...
  27. ncbi Tumour necrosis factor-alpha as a new therapeutic target for rheumatoid arthritis: an update
    A S M Giasuddin
    Dept of Biochemistry, Medical College for Women and Hospital, Uttara, Dhaka
    Bangladesh Med Res Counc Bull 31:88-94. 2005
    ..g. TNFalpha, in RA as well as in other inflammatory autoimmune diseases in the near future...
  28. ncbi Biologic therapeutics in the treatment of psoriasis. Part 1: review
    Richard G Langley
    Department of Medicine, Dalhousie University, Halifax, NS, Canada
    J Cutan Med Surg 11:99-122. 2007
    ....
  29. ncbi The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease
    Ziad Reguiai
    Department of Dermatology, Hopital Robert Debre, Reims, France
    Am J Clin Dermatol 8:67-77. 2007
    ..Additional comparative long-term studies are needed to determine the long-term efficacy and safety of anti-TNFalpha therapy and define its role in the management of PG, with or without accompanying IBD...
  30. ncbi Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab
    E Di Poi
    Division of Rheumatology, DPMSC, School of Medicine, University of Udine, Udine, Italy
    Clin Exp Rheumatol 25:85-7. 2007
    ..A moderate or good response was achieved with etanercept in 13 out of 18 patients. From our experience, etanercept can be considered as a good alternative choice when infliximab has failed...
  31. ncbi Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors
    Wesley Mizutani
    Talbert Medical Group, Fountain Valley, California, USA
    Manag Care Interface 16:44-50, 55. 2003
    ..Managed care organizations should encourage early diagnosis of rheumatoid arthritis, referral to a rheumatologist, and treatment with agents that reduce the overall costs of this debilitating disease...
  32. pmc Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis
    M Flendrie
    UMC Nijmegen, The Netherlands
    Ann Rheum Dis 62:ii30-3. 2003
    ..Adverse events which occurred, leading to discontinuation, were similar to those from previous reports...
  33. ncbi Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis
    Samuele M Marcora
    School of Sport, Health, and Exercise Sciences, University of Wales, Bangor, United Kingdom
    Am J Clin Nutr 84:1463-72. 2006
    ..Tumor necrosis factor (TNF) is an important mediator of cachexia, and its blockade prevents catabolism in animal models. However, little evidence shows that anti-TNF therapy is effective in treating cachexia in humans...
  34. ncbi [The role of biological agents in the treatment of psoriatic arthritis, literature review]
    Éva Koó
    Budai Irgalmasrendi Kórház, II Reumatológiai Osztály
    Orv Hetil 147:1963-70. 2006
    ..TNF-alpha inhibitors available in Hungary (infliximab, etanercept, adalimumab) are potential therapies for patients who have not adequately responded to traditional disease-modifying antirheumatic drugs...
  35. ncbi [Tumor necrosis factor blocking agents: a review. Part I: Clinical efficacy evaluation]
    C Rodriguez Moreno
    Servicios de Farmacología Clínica, Complexo Hospitalario Universitario, Santiago de Compostela, A Coruna, Spain
    An Med Interna 23:37-45. 2006
    ..The purpose of this article is to review the evidence about benefits and risk associated with the use of TNF-blockers in approved indications and to provide practical recommendations for its use in the management of these conditions...
  36. ncbi What have we learned in dermatology from the biologic therapies?
    Brian J Nickoloff
    J Am Acad Dermatol 54:S143-51. 2006
    ..Here, we review the history of our understanding of inflammatory dermatoses, traditional and new treatment approaches, and future directions for research and therapy in this area...
  37. pmc Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients
    P Efthimiou
    Division of Allergy, Immunology and Rheumatology, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, USA
    Ann Rheum Dis 65:1233-6. 2006
    ..To understand the use of tumour necrosis factor (TNF)alpha inhibitors in refractory dermatomyositis and polymyositis in an academic centre...
  38. ncbi Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?
    C Y Lu
    School of Medical Sciences, University of New South Wales, NSW, Australia
    Intern Med J 36:19-27. 2006
    ..Examination of utilization data is important for assessing the broader implications of arrangements for access to expensive pharmaceuticals under schemes such as the PBS...
  39. pmc Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
    P Geborek
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Ann Rheum Dis 64:699-703. 2005
    ..To determine whether TNF blockers increase tumour risk in patients with RA...
  40. pmc Treatment continuation in patients receiving biological agents or conventional DMARD therapy
    A Zink
    German Rheumatism Research Centre, Berlin, Germany
    Ann Rheum Dis 64:1274-9. 2005
    ....
  41. ncbi Role of biological agents in immune-mediated inflammatory diseases
    Petros Efthimiou
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York 10021, USA
    South Med J 98:192-204. 2005
    ..Their role is currently being defined in other autoimmune disorders such as uveitis, sarcoidosis, interstitial lung disease, vasculitis, inflammatory myopathies, graft-versus-host disease, and Sjögren syndrome...
  42. ncbi [Applications of monoclonal antibodies and biotechnology products in the treatment of chronic inflammatory diseases]
    J L Marenco de la Fuente
    Seccion de Reumatologia, Hospital de Valme, Facultad de Medicina, Sevilla
    Rev Clin Esp 205:127-36. 2005
    ..Other potential biological drugs still in investigational phase are mentioned...
  43. ncbi Update on the mechanisms and efficacy of biological therapies for psoriasis
    John Koo
    UCSF Psoriasis Treatment Center, Department of Dermatology, University of California, 515 Spruce Street, San Francisco, CA 94118, USA
    J Dermatol Sci 38:75-87. 2005
    ....
  44. ncbi Psoriatic arthritis
    Philippe Goupille
    EA 3853 Immuno Pharmaco Génétics of Therapeutic Antibodies IPGA, and Rheumatology Department, Trousseau Teaching Hospital, Francois Rabelais University, 37044 Tours cedex 9, France
    Joint Bone Spine 72:466-70. 2005
    ..TNF-alpha antagonists constitute a breakthrough in the management of psoriatic arthritis. Similar to rheumatoid arthritis and ankylosing spondylitis, psoriatic arthritis is entering a new era of evaluation and treatment...
  45. ncbi Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
    K L Hyrich
    Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, UK
    Rheumatology (Oxford) 45:1558-65. 2006
    ..These drugs are expensive and have the potential of serious toxicity. Therefore, it would be ideal to predict the patients who will respond, so that the use of these drugs can be targetted...
  46. ncbi Ankylosing spondylitis: new treatment modalities
    Jan Brandt
    Rheumatologische Praxisgemeinschaft, Berlin, Germany
    Best Pract Res Clin Rheumatol 20:559-70. 2006
    ..Ongoing research has proven these agents to be efficacious and safe in the short and medium term. Further, longer-term trials are awaited to address the issue of whether these therapies are true disease modifiers in AS...
  47. ncbi Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study
    Alfons A den Broeder
    Department of Rheumatology and Orthopaedic Surgery, Sint Maartenskliniek, The Netherlands
    J Rheumatol 34:689-95. 2007
    ..To identify risk factors for surgical site infection (SSI) in patients with rheumatoid arthritis (RA) with special attention for anti-tumor necrosis factor (anti-TNF) treatment...
  48. ncbi The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis
    Ori Elkayam
    Department of Rheumatology, Tel Aviv Sourasky Medical Center, Israel
    Semin Arthritis Rheum 33:283-8. 2004
    ..To assess the effect of anti-tumor necrosis factor (TNF) alpha therapies on the immunogenicity of pneumococcal vaccination in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS)...
  49. ncbi Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents
    R M Fleishmann
    University of Texas, Southwestern Medical Center at Dallas Dallas, Texas, USA
    Clin Exp Rheumatol 20:S35-41. 2002
    ..Post approval, several safety concerns, including patients at risk for serious infection and the emergence of latent tuberculosis and other opportunistic infections have emerged with the use of anti TNF therapy...
  50. ncbi The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists
    Jennifer Cole
    Department of Pharmacy, Veterans Affairs North Texas Health Care System VANTHCS, Dallas, TX, USA
    Rheumatol Int 27:369-73. 2007
    ..940. Mortality rates were not significantly different: TNF-alpha 4 (3.8%), RA control 7 (7%), non-RA control 11 (11%); P = 0.147. Our study showed no difference between the three groups in either CHF exacerbation or mortality...
  51. ncbi Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review
    R Ariza-Ariza
    Rheumatology Service, Hospital Universitario Virgen Macarena, Seville, Spain
    Rheumatology (Oxford) 46:529-32. 2007
    ..To estimate the proportion of rheumatoid arthritis (RA) patients on anti-tumour necrosis factor (anti-TNF) who require dose escalation...
  52. ncbi New biologic therapies for psoriatic disease
    Kimberly A Bohjanen
    Department of Dermatology, University of Minnesota Medical School, USA
    Minn Med 87:34-6. 2004
    ....
  53. ncbi [The role of biologic agents in the therapy of ankylosing spondylitis]
    Pál Géher
    Semmelweis Egyetem, Általános Orvostudományi Kar, Ill Belgyógyászati Klinika, Reumatológiai és Fizioterápiás Tanszéki Csoport, Budai Irgalmasrendi Kórház, I Reumatológiai Osztály, Budapest
    Orv Hetil 147:1203-13. 2006
    ..Though individual admission is feasible, biologic drugs are not under reimbursement in Hungary. High drug costs makes the implementation of this new therapeutic opportunity difficult in the daily medical practice...
  54. ncbi Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients
    C Salliot
    Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Rheumatology (Oxford) 46:327-34. 2007
    ..To evaluate the rate of infections in rheumatic patients treated with tumour necrosis factor (TNF)-alpha blockers in daily practice and to determine potential risk factors of infections...
  55. ncbi Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
    W G Dixon
    British Society for Rheumatology Biologics Register Control Centre Consortium, Manchester, UK
    Arthritis Rheum 54:2368-76. 2006
    ....
  56. ncbi TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis
    Cristina Russo
    Dipartimento di Medicina Interna e Specialistica, Ascoli Tomaselli Hospitals, University of Catania, Italy
    Clin Sci (Lond) 109:135-42. 2005
    ....
  57. ncbi Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2
    Beverly E Sha
    Section of Infectious Diseases, Department of Medicine, Rush Medical College, Chicago, Illinois 60612 3833, USA
    AIDS Res Hum Retroviruses 18:661-5. 2002
    ..Pretreatment with etanercept may blunt activation of IL-6 and CRP expression induced by rhIL-2. The safety and utility of etanercept in HIV-infected persons should be explored further...
  58. ncbi Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept
    Boback Berookhim
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA
    Cutis 74:245-7. 2004
    ..To our knowledge, this is the first report of its efficacy in the treatment of PV...
  59. ncbi Biological modifier therapy for the treatment of rheumatoid arthritis
    John K Jenkins
    Department of Medicine, University of Mississippi Medical Center, Jackson 39216, USA
    Am J Med Sci 323:197-205. 2002
    ..The success of these agents underscores the investigative approaches to the pathogenesis of RA and the appropriate design of pharmaceutical agents to target specific proinflammatory molecules...
  60. ncbi [New drugs and treatment strategies for rheumatoid arthritis]
    Flavio Fantini
    Cattedra di Reumatologia Università, Unità Operativa di Reumatologia, Azienda Ospedaliera Istituto Ortopedico Gaetano Pini, Milano
    Recenti Prog Med 94:361-79. 2003
    ....
  61. ncbi Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum
    Juanita H Vernooy
    Nutrition and Toxicology Research Institute Maastricht, Department of Pulmonology, Maastricht University, The Netherlands
    Am J Respir Crit Care Med 166:1218-24. 2002
    ....
  62. ncbi Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis
    Christine R Culy
    Adis International Limited, Auckland, New Zealand
    Drugs 62:2493-537. 2002
    ..Well controlled studies have also demonstrated the efficacy of etanercept in patients with psoriatic arthritis or polyarticular-course juvenile rheumatoid arthritis...
  63. ncbi Anti-tumour necrosis factor (TNF)-alpha therapy in undifferentiated spondyloarthropathy
    S Schnarr
    Hannover Medical School, Department of Internal Medicine, University of Hannover, Germany
    Clin Exp Rheumatol 20:S126-9. 2002
    ..This article summarises the preliminary results of 11 uSpA patients in 4 different trials treated with TNFalpha inhibitors...
  64. ncbi 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University ofAuckland, New Zealand
    Invest New Drugs 20:281-95. 2002
    ..Similar to many biological response modifiers, DMXAA alone did not show striking anti-tumour activity in patients...
  65. ncbi [The pulmonological manifestations of rheumatoid arthritis]
    György Bernscherer
    Bernscherer és Tsa Bt Budapest
    Orv Hetil 149:1355-61. 2008
    ..These are the biological response modifiers. Their main representatives are infliximab, adalimumab, and etanercept...
  66. ncbi The role of natural biopolymers in genotoxicity of mutagens/carcinogens elimination
    Eva Miadokova
    Department of Genetics, Comenius University, Mlynska dolina, B L, Bratislava, Slovak Republic
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149:493-6. 2005
    ..cell wall of baker's yeast Saccharomyces cerevisiae is included into the class of biopolymers known as biological response modifiers (BRMs) with a broad range of activities, above all ones interfering with cancer therapy...
  67. ncbi Antiviral activity of biological response modifiers in a murine model of AIDS. Requirement for augmentation of natural killer cell activity and synergy with oral AZT
    P L Black
    Southern Research Institute Frederick Research Center, MD, USA
    Int J Immunopharmacol 18:633-50. 1996
    We employed the Rauscher murine leukemia virus (RMuLV) as a murine retrovirus model of AIDS, to test biological response modifiers (BRM) and antiviral agents for potential therapeutic activity against the human immunodeficiency virus (..
  68. ncbi Biologically active compounds from Aphyllophorales (polypore) fungi
    Jordan K Zjawiony
    Department of Pharmacognosy and National Center for Natural Product Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, Mississippi 38677 1848, USA
    J Nat Prod 67:300-10. 2004
    ..These high molecular weight compounds, often called biological response modifiers (BRM), or immunopotentiators, prevent carcinogenesis, show direct anticancer effects, and prevent ..
  69. ncbi Cereal non-cellulosic polysaccharides: structure and function relationship - an overview
    G Muralikrishna
    Department of Biochemistry and Nutrition, Central Food Technological Research Institute, Mysore, Karnataka, India
    Crit Rev Food Sci Nutr 47:599-610. 2007
    ..1 --> 3),(1 --> 4)-beta -glucans are known as biological response modifiers (BMS) as they are believed to modulate the immune response...
  70. ncbi Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder
    A Morales
    Department of Urology, Queen s University, Kingston, Canada
    J Urol 166:1633-7; discussion 1637-8. 2001
    ..This result has led to the search for other active and safer biological response modifiers. We investigated the efficacy of a mycobacterial cell wall extract (MCWE) from Mycobacterium phlei, ..
  71. ncbi Biological response modifiers for the treatment of superficial bladder tumors
    A R Zlotta
    Department of Urology, Erasme Hospital, University Clinics of Brussels, Belgium
    Eur Urol 37:10-5. 2000
    For more than 20 years, superficial bladder tumors have been demonstrated to be sensitive to several biological response modifiers and especially to immunomodulators...
  72. ncbi Normal tissue complications after radiation therapy
    Jolyon H Hendry
    International Atomic Energy Agency, Division of Human Health, Applied Radiobiology and Radiotherapy Section, Vienna, Austria
    Rev Panam Salud Publica 20:151-60. 2006
    ..Potential modification to treatments include the use of biological response modifiers. The introduction of "response prediction" modifications to treatments might also be available in the ..
  73. ncbi Augmentation of anti-tumor immunity in low-responder mice by various biological response modifiers: analysis of effector mechanism
    T Toko
    Department of Immunology, Kochi Medical School
    Jpn J Cancer Res 80:1212-9. 1989
    In order to elucidate the role of biological response modifiers (BRMs) in anti-tumor immunotherapy, we examined their effect on the induction of anti-tumor immunity in low-responder mice which hardly exhibit anti-tumor resistance against ..
  74. pmc Cancer Research Campaign review of radiobiology research
    A Horwich
    Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 67:198-201. 1993
    ..of response using drug/radiation protocols, targeting techniques, growth factors and other biological response modifiers to support normal tissues, and modulation of DNA repair...
  75. ncbi Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies
    M Graf
    Medical Department 3, Klinikum Grosshadern, University of Munich, Munich, Germany
    Eur J Haematol 75:477-84. 2005
    ..With respect to the individual PRR-status the benefit of biological response modifiers as priming agents, differentiation mediators or factors influencing cellular metabolisms inducing ..
  76. ncbi Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan
    C J Langer
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 15:19-24. 2001
    ..Planned combinations with new chemotherapeutic agents and biological response modifiers may provide additional treatment options.
  77. ncbi Imexon and biological response modifiers in murine models of AIDS
    M A Chirigos
    United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, Frederick, MD 21702
    Int J Immunopharmacol 13:33-41. 1991
    ..model of the human acquired immune deficiency syndrome for testing the ability of antiviral agents and biological response modifiers (BRM) to suppress viremia and retroviral disease...
  78. ncbi Cytokines and cognition--the case for a head-to-toe inflammatory paradigm
    Craig J Wilson
    St Vincent Institute on Aging, St Vincent Hospitals and Health Services, Indianapolis, Indiana 46260, USA
    J Am Geriatr Soc 50:2041-56. 2002
    ..Peripheral administration of certain cytokines as biological response modifiers produces adverse cognitive effects in animals and humans...
  79. ncbi The rationale and future potential of angiogenesis inhibitors in neoplasia
    G Gasparini
    Division of Medical Oncology, Azienda Ospedali Riuniti Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Drugs 58:17-38. 1999
    ..through modulation of neovascularisation, antiangiogenic agents need to be developed and evaluated as biological response modifiers. Therefore, adequate and well designed clinical trials should be performed for a proper evaluation of ..
  80. pmc A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease
    D J Gottlieb
    Department of Haematology, Royal Free Hospital, London, UK
    Br J Cancer 60:610-5. 1989
    b>Biological response modifiers such as interleukin 2 (IL2) may be most effective in the setting of minimal residual disease...
  81. ncbi Retinoids as critical modulators of immune functions: new therapeutic perspectives for old compounds
    Michele Montrone
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico IRCCS, National Cancer Institute, 33081, Aviano PN, Italy
    Endocr Metab Immune Disord Drug Targets 9:113-31. 2009
    ..These biological response modifiers exert their pleiotropic effects through the interaction with nuclear receptors, defined as retinoic ..
  82. ncbi Sickness behaviour, an animal equivalent to human quality of life, is improved in septic rats by G-CSF and antibiotic prophylaxis
    A Bauhofer
    Institute of Theoretical Surgery, University of Marburg, Baldingerstrasse, 35033 Marburg, Germany
    Langenbecks Arch Surg 386:132-40. 2001
    New biological response modifiers are usually tested in reductionistic, pharmacological animal models by the determination of mechanistic endpoints (mortality rate, cellular/physiological parameters)...
  83. ncbi Performance and immune responses to dietary beta-glucan in broiler chicks
    C M Cox
    Avian Immunobiology Laboratory, Department of Animal and Poultry Sciences, Virginia Tech, Blacksburg, VA, USA
    Poult Sci 89:1924-33. 2010
    ..Among immunomodulators, beta-glucans are known as biological response modifiers due to their ability to activate the immune system...
  84. pmc Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids
    T Brodowicz
    Clinical Division of Oncology, Department of Medicine I, University Hospital, Vienna, Australia
    Br J Cancer 80:1350-8. 1999
    ..Among many other biological response modifiers known to influence these mechanisms, the efficacy of retinoids and interferons in the treatment of ..
  85. ncbi The probiotic paradox: live and dead cells are biological response modifiers
    Clifford A Adams
    ANOZENE Nutritional Sciences, Antwerp, Belgium
    Nutr Res Rev 23:37-46. 2010
    ..However, the use of dead probiotics as biological response modifiers has several attractive advantages; such products would be very safe and have a long shelf-life.
  86. ncbi Beta-glucan-indomethacin combination produces no lethal effects
    Vaclav Vetvicka
    University of Louisville, Department of Pathology, Louisville, KY, USA
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 153:111-6. 2009
    ..They are typical biological response modifiers with pronounced immunomodulating activity. However, some questions about possible side effects remain.
  87. ncbi Protective effects of fungal (1-->3)-beta-D-glucan derivatives against oxidative DNA lesions in V79 hamster lung cells
    Darina Slamenova
    Cancer Research Institute, Slovak Academy of Sciences, 833 91 Bratislava, Slovakia
    Cancer Lett 198:153-60. 2003
    beta-Glucans belong to the class of substances known as biological response modifiers with a broad range of activity...
  88. ncbi Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies
    Luca Laurenti
    Istituto di Semeiotica Medica, Divisione di Ematologia, Policlinico A Gemelli, Largo A Gemelli, 8 00168 Rome, Italy
    Haematologica 87:59-66. 2002
    ....
  89. ncbi Yeast-derived beta-glucan in combination with anti-tumor monoclonal antibody therapy in cancer
    Jingjing Liu
    Tumor Immunobiology Program, James Graham Brown Cancer Center, Department of Microbiology and Immunology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA
    Recent Pat Anticancer Drug Discov 4:101-9. 2009
    ..beta-Glucans have been used to treat cancer and infectious disease for many years as biological response modifiers with varying and unpredictable efficacy...
  90. ncbi Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under simulated conditions of joint stress
    L Lippiello
    Nutramax Laboratories Inc, 2208 Lakeside Boulevard, Edgewood, MD 21040, USA
    Osteoarthritis Cartilage 11:335-42. 2003
    ..To test the hypothesis that chondrocytes are more responsive to the chondroprotective agents, glucosamine (glcN) and chondroitin sulfate (CS), under in vitro conditions simulating in vivo joint stress...
  91. ncbi Structure and function of sinusoidal lining cells in the liver
    E Wisse
    Laboratory for Cell Biology and Histology, Brussels Jette, Belgium
    Toxicol Pathol 24:100-11. 1996
    ..The number and cytotoxicity of pit cells can be considerably enhanced with biological response modifiers, such as Zymosan or interleukin 2 (8)...
  92. ncbi Oral beta-glucan adjuvant therapy converts nonprotective Th2 response to protective Th1 cell-mediated immune response in mammary tumor-bearing mice
    Jarek Baran
    Tumor Immunobiology Program, James Graham Brown Cancer Center, University of Louisville, KY, USA
    Folia Histochem Cytobiol 45:107-14. 2007
    Beta (1-3)-D-glucans were identified almost 40 years ago as biological response modifiers that stimulated tumor rejection...
  93. ncbi Differential expression of a stress-modulating gene, BRE, in the adrenal gland, in adrenal neoplasia, and in abnormal adrenal tissues
    J Miao
    Department of Clinical Oncology, Sir Y K Pao Centre for Cancer, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China
    J Histochem Cytochem 49:491-500. 2001
    ..Many of these biological response modifiers are responsible for various pathological conditions, including inflammation, infection, cachexia, ..
  94. ncbi Protection against murine cytomegalovirus infection in aged mice and mice with severe combined immunodeficiency disease with the biological response modifiers polyribosinic-polycytidylic acid stabilized with L-lysine and carboxymethylcellulose, maleic anh
    S C Kunder
    Department of Microbiology and Immunology, Medical College of Pennsylvania, Philadelphia 19129
    Antiviral Res 21:233-45. 1993
    A variety of biological response modifiers (BRMs) have provided antiviral protection to immunocompetent mice, and this prompted us to determine their efficacy against murine cytomegalovirus (MCMV) infection in immunocompromised mice-..
  95. ncbi Idiopathic hirsutism
    R Azziz
    Department of Obstetrics and Gynecology, The University of Alabama at Birmingham, 35233 7333, USA
    Endocr Rev 21:347-62. 2000
    ..New therapeutic strategies such as laser epilation or the use of new biological response modifiers may play an important role in offering a more effective means of treatment to remove unwanted hair...
  96. ncbi Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer
    Jun Yan
    James Graham Brown Cancer Center, Tumour Immunobiology Program, University of Louisville, 580 S Preston Street, Louisville, KY 40202, USA
    Expert Opin Biol Ther 5:691-702. 2005
    Beta-glucans, biological response modifiers (BRMs) derived from the cell walls of yeast and other sources, have been demonstrated to prime leukocyte complement receptor 3 (CR3), thus enabling these cells to kill tumours opsonised with ..
  97. ncbi Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis
    Kristian Reich
    Dermatologikum Hamburg, Hamburg, Germany
    Curr Med Res Opin 24:1237-54. 2008
    The comparative effects of biological response modifiers (BRMs) on the severity of psoriasis and its effects on health-related quality of life (HRQoL) have not been evaluated.
  98. ncbi Structural development of biological response modifiers based on retinoids and thalidomide
    Yuichi Hashimoto
    Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1 1 1 Yayoi, Bunkyo ku, Tokyo, 113 0032, Japan
    Mini Rev Med Chem 2:543-51. 2002
    ..In this situation, biological response modifiers (BRM's), which are not based on selective toxicity, are expected to be useful...
  99. ncbi [Brain metastases of malignant melanomas]
    C Boaziz
    Service d Oncologie Medicale, Hopital Avicenne, Bobigny, France
    Bull Cancer 78:347-53. 1991
    ..Neither do the biological response modifiers like Interleukin 2 (Il2) that leads to 25% response rate in disseminated melanoma...
  100. ncbi A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma
    E Bajetta
    Unit of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 87:219-22. 2001
    ....
  101. ncbi The effect of a bacterial vaccine on tumors and the immune response of ICR/Ha mice
    H F Havas
    Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140
    J Biol Response Mod 9:194-204. 1990
    ..MBV compares favorably with other biological response modifiers because of its enhancing effect on the immune response and its oncolytic properties at nontoxic levels.

Research Grants62

  1. Deep South Musculoskeletal (DSM) CERTs
    Kenneth G Saag; Fiscal Year: 2010
    ..Since 1998, over 15 new treatments have been FDA approved for MSDs, including novel biological response modifiers. Despite significant efficacy in clinical trials, questions and concerns persist about the safety, ..
  2. Modulating Innate and Adaptive Immunity in Complicated Abdominal Sepsis
    Frederick A Moore; Fiscal Year: 2012
    ..b>Biological response modifiers (BRMs) have targeted individual components of the inflammatory response, microbial recognition, ..
  3. Prevalence and immunogenicity of HNA-3a and -3b antibodies and antigens
    RICHARD HERBERT ASTER; Fiscal Year: 2012
    ..fatality, is triggered by transfusion of blood products containing leukocyte antibodies and/or biological response modifiers to susceptible patients...
  4. ENHANCEMENT OF PDT USING BIOLOGICAL RESPONSE MODIFIERS
    David A Bellnier; Fiscal Year: 2010
    ....
  5. Validation of a Genomics Based Prognostic in Severe Trauma
    Lyle L Moldawer; Fiscal Year: 2013
    ..understanding of the basic pathophysiology of severe trauma and its sequelae, there are essentially no biological response modifiers that have proven successful in prospective, randomized clinical trials...
  6. Collection, Storage, Advertisements, & Distribut of Biological Response Modifiers
    HANNAH ELSON; Fiscal Year: 2010
    ..Between April 1996 and August 2008 the repository contractor distributed, on behalf of the NCI, over 43,000 vials of reagents to hundreds of institutions. ..
  7. Collection, Storage, Advertisements, &Distribut of Biological Response Modifiers
    HANNAH ELSON; Fiscal Year: 2009
    ..Between April 1996 and August 2008 the repository contractor distributed, on behalf of the NCI, over 43,000 vials of reagents to hundreds of institutions. ..
  8. Keratinocyte Costimulation and Th2-Cell Immune Deviation
    Anthony Gaspari; Fiscal Year: 2009
    ..Similar mechanistic studies of the molecular basis of other skin diseases such as psoriasis have led to the development of biological response modifiers that are now in clinical use.
  9. Planning a Multi-Center Trial of Interferon-gamma in Trauma Patients
    RONALD GARY TOMPKINS; Fiscal Year: 2012
    ..A primary objective is to determine whether rhIFN-? reduces "time to recovery" and increases "organ-failure free days" in the subgroup of patients identified by the prognostic test to be at increased risk. ..
  10. PEDIATRIC ONCOLOGY GROUP
    Stephen Lauer; Fiscal Year: 2002
    ..in tumor-suppressor genes); in vitro sensitivity of leukemia cells to antineoplastic agents mid biological response modifiers; mechanisms of resistance of AML cells to alkylating agents; molecular neuro-oncology; and xenogeneic ..
  11. PERIODONTAL LIGAMENT CELL AUTOCRINE FACTOR
    VICTOR TERRANOVA; Fiscal Year: 1993
    ..b>Biological response modifiers to be co-examined along with the PDL-CTX and PDL-CTX-R (PDL-CTX-receptor) include FGF, PDGF, TGF-beta ..
  12. Antiviral Compounds for Human Papillomavirus 16
    Christopher Fisher; Fiscal Year: 2005
    ..Current treatments, which include surgery, freezing, noxious agents, and =biological response modifiers," are primitive or non-specific...
  13. OXIDANT STRESS AND ENDOTHELIAL CELL METABOLISM
    LORRAINE SORDILLO; Fiscal Year: 2001
    ..Se-deficient endothelial cells, 2) to evaluate the effects of Se deficiency on the production of such biological response modifiers as cytokines, PAF and NO in relation to altered eicosanoid production and 3) to evaluate the effects ..
  14. BINDING OF ALLERGENS TO LIPOSOMES FOR IMMUNOTHERAPY
    ARISTO WOJDANI; Fiscal Year: 1990
    ..used by other investigators, in this study our major goal is to encapsulate standardized allergens and biological response modifiers (BRMs) to different liposomes and study the effect of this modification on their allergenicity and ..
  15. Biowarfare applications of a new immunoregulator
    KENNETH WILLEFORD; Fiscal Year: 2003
    ..Scientists at GeneBact Biotechnologies, Inc. have discovered a new class of Biological Response Modifiers from mammalian serum that we refer to as the Immune Cell Proliferation Factors ("ICPF")...
  16. PRIMARY BREAST CANCER THERAPY GROUP-NSABP
    Daniel Karp; Fiscal Year: 1991
    ..oncogenes, 3) estrogen receptor assay research development and 4) clinical application of the role of biological response modifiers such as IL-2 and lymphokine activated cytotoxity and tuftsin and mechanisms of estrogen/tamoxofin on ..
  17. NOVEL MARROW PURGING REGIMENS IN LEUKEMIA
    Joseph Wiley; Fiscal Year: 1992
    ..will develop principles for the application of combination purging with chemotherapeutic agents and biological response modifiers in clinical treatment of leukemic marrow and form the basis for the applicant's career development as ..
  18. PEDIATRIC ONCOLOGY GROUP--PHASE I TRIALS IN CHILDREN
    Sharon Murphy; Fiscal Year: 2000
    ..are to: (1) establish the maximum tolerated dose and dose-limiting toxicities of new cytotoxic agents, biological response modifiers, or maturational agents; (2) determine the quantitative and qualitative toxicity of new agents, the ..
  19. REGULATION OF PRODUCTION OF GAMMA INTERFERON IN TUMOR
    Howard Johnson; Fiscal Year: 1990
    ..of the brain where AVP and its receptor are present as well as cells capable of producing classic biological response modifiers. The objective of this proposal is to determine the mechanism by which AVP positively regulates ..
  20. PHASE I/II TRIAL, INTRACAVITARY LAK/IL-2 IN BRAIN TUMORS
    Maxim Koslow; Fiscal Year: 1991
    ..Alternative approaches to cancer therapy have focused on the use of biological response modifiers (BRMs) as antitumor agents...
  21. CLINICAL TRIALS OF BIOLOGICAL RESPONSE MODIFIERS
    MICHAEL LOTZE; Fiscal Year: 1999
    ..4) More approaches utilizing T-cell defined tumor epitopes in constructing tumor vaccine. ..
  22. TUMOR GROWTH INHIBITION BY INTERFERON B AND RETINOIDS
    DHAN KALVAKOLANU; Fiscal Year: 2001
    Interferons (IFNs) and retinoids are powerful biological response modifiers. Although they are effective growth inhibitors of certain transformed cells, both these agents have limited efficacy as single agents against many tumors...
  23. TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
    TSANN CHU; Fiscal Year: 1990
    ..Effectiveness of both therapies will be potentiated by biological response modifiers. The proposed approaches to the use of a unique monoclonal antibody in targeting and therapy of ..
  24. ANTINEOPLASTIC ALKYLGLYCEROLIPIDS
    CLAUDE PIANTADOSI; Fiscal Year: 1990
    ..ALPs may be directly cytotoxic to tumor cells or may function as biological response modifiers, or may exhibit both effects...
  25. BIOLOGICAL RESPONSE MODIFIERS IN TRANSFUSION MEDICINE
    Edward Snyder; Fiscal Year: 1993
    ..Adapted from applicant's abstract)Support is requested for a scientific meeting entitled "The Role of Biological Response Modifiers in Molecular and Clinical Transfusion Medicine", to be held Thursday- Friday, September 9-10, 1993 in ..
  26. HSV VECTORS FOR THE DESTRUCTION OF BRAIN TUMORS
    Nigel Fraser; Fiscal Year: 2005
    ..the effectiveness of HSV-1 based tumor destruction by engineering HSV-1 mutants that will express biological response modifiers, such as an angiogenesis inhibitor specifically within tumors cells...
  27. EASTERN COOPERATIVE ONCOLOGY GROUP
    Barbara Grant; Fiscal Year: 1992
    ..New initiatives in treatment with biological response modifiers such as interleukin-2 and LAK cells and a planned program of autologous bone marrow transplantation ..
  28. PRODUCTION OF NATURAL KILLER CELLS
    SYLVIA POLLACK; Fiscal Year: 1992
    ..be used to assess the effects on NK lineage cells of the neutrophilia-inducing tumor CE1460 and the biological response modifiers AIPP (2-amino-5-iodo-6-phenyl-4-pyrimidinone) and OK-432 (a pharmaceutical preparation of ..
  29. TUMOR NECROSIS FACTOR INDUCES A NEW REGULATORY CYTOKINE
    PRAVIN SEHGAL; Fiscal Year: 1991
    ..These studies are likely to provide insights important to the use of biological response modifiers such as TNF and IFN-Beta2 in the clinic against neoplastic diseases.
  30. FIBROBLAST ACTIVATION
    Arnold Postlethwaite; Fiscal Year: 1993
    ..The macrophage produces two classes of biological response modifiers, [interleukin 1 (IL-1) and transforming growth factor Beta (TGF) Beta] that are capable of modulating ..
  31. Finding membrane proteins in cutaneous T-cell lymphomas
    PRISKA VON HALLER; Fiscal Year: 2003
    ..Despite the impact of biological response modifiers, such as interferon alpha, there still remains up to 25 to 50% of patients who present with advanced ..
  32. INTERNATIONAL CONFERENCE ON RENAL CARCINOMA
    Jean de Kernion; Fiscal Year: 1992
    ..The second session will consider tumor suppressor genes, oncogenes and growth factor. The third session is on determinants of biological behavior: invasion and metastases. The fourth session will cover biological response modifiers.
  33. Neurobiology of MIF in development and disease
    Bradley Pearce; Fiscal Year: 2007
    ..2, and its amino acid sequence has minimal homology with other identified biological response modifiers in mammals...
  34. BIOLOGICAL MODIFIERS
    Robert Sidwell; Fiscal Year: 1993
    Partial support is sought for the 2nd International Congress on Biological Response Modifiers (BRM), which is being organized by the Inter-American Society for Chemotherapy, Inc. (IASC)...
  35. CLINICAL RESEARCH IN NEURO-ONCOLOGY
    ROY PATCHELL; Fiscal Year: 2004
    ..uses of the device, including use with non-conventional agents such as anti-angiogenesis factors, biological response modifiers, radiation cell sensitizers, and other compounds. Dr...
  36. Cancer Immunotherapy w/In-Situ Maturated Dendritic cells
    Eli Gilboa; Fiscal Year: 2006
    ..the optimal conditions for in situ maturation using classical adjuvants and whether local injection of biological response modifiers (BRMs) in the form of mRNA can contribute to the generation of potent immunostimulatory DC...
  37. CLINICAL TRIALS OF BIOLOGICAL RESPONSE MODIFIERS-TASK A
    Albert LoBuglio; Fiscal Year: 1999
    ..We will be further evaluating other new targeting agents for inclusion into future phase I and phase II clinical trials. ..
  38. MALIGNANT CELL GROWTH MODULATION BY INTERLEUKIN-1
    EDWIN GAFFNEY; Fiscal Year: 1990
    ..of this dual- role is unclear, but bifunctional regulatory activities have been observed for other biological response modifiers. This proposal outlines three approaches to elucidate the mechanisms underlying the growth modulating ..
  39. BIOLOGICAL RESPONSE MODIFIERS
    JOAN RENER; Fiscal Year: 1990
    ..In some instances production and initial purification of biologics, such as monoclonal antibodies for clinical trails is performed...
  40. ANIMAL MODELS OF HUMAN VIRAL INFECTIONS
    Robert Sidwell; Fiscal Year: 2000
    ..mice which have been used successfully for evaluating influenza virus-inhibitory compounds and biological response modifiers (BRMs) in the now-terminating NIAID Animal Models contract...
  41. Rapid Screen for Genotoxicants, Chemoprotectors, and Radioprotectors
    Stephen Dertinger; Fiscal Year: 2006
    ..This project addresses a stated need of investigators working to develop the next generation of biological response modifiers (BRMs)...
  42. SHARED TUMOR IDIOTOPES OF B CELL NEOPLASMS
    Richard Miller; Fiscal Year: 1991
    ..anti-Id MoAbs conjugated to cytotoxic radioisotopes or administered in conjunction with other biological response modifiers. Overall, the results of the Phase 1 and 2 studies should lead to the practical development of anti-Id ..
  43. PHASE I/II CLINICAL STUDIES OF BIOLOGICAL RESPONSE
    JANICE GABRILOV; Fiscal Year: 1993
    ..protocol for each trial will be developed by the contractor in collaboration with staff of the Biological Response Modifiers Program, NCI, and protocols must have NCI and FDA approval before they can be activated...
  44. INTERNATIONAL CONFERENCE ON IMMUNOMODULATING DRUGS
    Hideyo Yamaguchi; Fiscal Year: 1992
    ..applications of immunomodulating drugs either alone or in combination therapies, peptides as immunomodulating agents, immunotherapy of infectious diseases, and the role of various biological response modifiers in clinical therapies.
  45. CUTANEOUS ONCOLOGY
    Madeleine Duvic; Fiscal Year: 2004
    ..Young physicians and students who receive advanced training in the proper detection, prevention, and treatment of skin cancers will be a resource and may improve outcomes for patients of the future. ..
  46. TRAINING GRANT IN MOLECULAR CARDIOLOGY
    Mark Entman; Fiscal Year: 2008
    ..This integrated design has consistently proven to be effective in providing successful independent and competitive investigators in molecular biology of cardiovascular medicine. ..
  47. Pathogenesis and Treatment of Alcohol-Induced Cirrhosis
    Bruce Cronstein; Fiscal Year: 2007
    ..Specific Aim: Investigate the intracellular mechanisms involved in signaling an increase in collagen production (cAMP pathway, MAPK pathway, CREB phosphorylation). ..